Back
22 November 2024
As reported by the ITA previously, a sample collected during a targeted out-of-competition test on 17 February 2024 from Tuğrulhan Erdemir returned an Atypical Finding (ATF)¹ for the prohibited substance hydrochlorothiazide.
Hydrochlorothiazide is prohibited under the 2024 WADA Prohibited list as a diuretic and masking agent (S.5). It is prohibited at all times (in-competition and out-of-competition).
On 24 July 2024, and further to a fully fledged hearing on the issue of the provisional suspension, CAS ADD issued an order confirming and maintaining the provisional suspension imposed on Tuğrulhan Erdemir which also extended to the Olympic Games Paris 2024.
The proceedings resumed on the issue of the asserted ADRV and related consequences under the International Boxing Association (IBA) Anti-Doping Rules (IBA ADR).
A second hearing pertaining to the merits of the case took place before the CAS ADD on 31 October 2024 at which the ITA represented the IBA. After hearing the parties and considering the written submissions and evidence, CAS ADD found that the athlete had committed an ADRV for the presence of a prohibited substance in accordance with Article 2.1 of the IBA ADR.
CAS ADD sanctioned Tuğrulhan Erdemir with 2 years of ineligibility. All results obtained by the athlete from 17 February 2024 (date of the ADRV) until 10 July 2024 (date of the provisional suspension) are disqualified.
The athlete has a right of appeal before the appeal division of CAS.
The ITA will not comment further on this case.
